focus -WSS

focus

author：hotspot 2025-09-29 21:29:03 - browse：858

A young boy died in a trial for Pfizer’s experimental gene therapy for Duchenne muscular dystrophy, the company told patient advocates Tuesday.

The boy was enrolled in Daylight, a trial studying the treatment in boys aged 2 or 3. The boy had received the therapy early last year, Pfizer told the advocates in a note posted online by Parent Project Muscular Dystrophy.

Pfizer said the boy died of cardiac arrest, but that it was still working to understand what happened and the exact cause.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： In diabetes hearing, Sanders takes on a new foe: food makers

WSS

Even great ERs can’t make up for American health disparities

Even great ERs can’t make up for American health disparities

ARCH Venture Partners is raising $3 billion for a life sciences fund

FDA needs staff influx to meet gene therapy needs, Marks says

STAT letters to the editor on burnt

Americans' trust in science, scientist continues decline: Report

focus

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

knowledge

Duchenne breakthrough therapy leaves behind pioneering families

Pregnancy discrimination could be enabled by AI

Hepatitis C has a cure — but many Americans still lack access to it

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

Jerome Adams on the need for new antivirals for Covid

Quicker fix for pulse oximeters urged during FDA public meeting

In age of alternative facts, a scholarly course on calling out crap

AI models in health care face new federal disclosure requirements

Novavax promises a turnaround & Lilly roils the obesity market

Congressmen charge Covid hearing ‘could have been an email’

entertainment

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

Patients' immediate access to test results puts radiologists in a bind

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

Quicker fix for pulse oximeters urged during FDA public meeting

Covid misinformation case heads to Supreme Court

Roche to buy Carmot Therapeutics, developer of obesity drugs

focus

knowledge

explore

leisure time